Intravesical Administration of Durvalumab for High-risk Non–muscle-invasive Bladder Cancer: A Phase 2 Study by the Hellenic GU Cancer Group

This article has no abstract
Epistemonikos ID: dca1328ba0bbc90eb01d5883079d33a740fab519
First added on: Jan 31, 2025